Background Nonvitamin K antagonist oral anticoagulants (NOACs) are alternatives to
warfarin in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs …

Background and Purpose—There are limited real-world data comparing the effectiveness
and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians …

Abstract Objectives: Dabigatran, rivaroxaban, apixaban, and edoxaban are nonvitamin K
antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with …

Background No studies have directly compared the effectiveness and safety of dabigatran
and rivaroxaban using US Medicare data. Objective Our objective was to compare …

Aims We used the US Department of Defense Military Health System database to compare
the safety and effectiveness of direct oral anticoagulants (DOACs) in patients with non …

Abstract Introduction and Objectives Recently, three novel non-vitamin K antagonist oral
anticoagulants received approval for reimbursement in Portugal for patients with non …

Background—The safety and effectiveness of non–vitamin K antagonist (VKA) oral
anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-naive …

Novel oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, represent new
options for preventing stroke in patients with atrial fibrillation, as shown by the results from …

Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

Background Atrial fibrillation (AF) is the most common cardiac arrhythmia associated with an
increased risk of stroke and thromboembolism. Anticoagulation with Vitamin K antagonists …